MCID: OVR096
MIFTS: 27

Overlap Myositis

Categories: Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Overlap Myositis

MalaCards integrated aliases for Overlap Myositis:

Name: Overlap Myositis 58
Adult-Onset Overlap Myositis 58
Non-Specific Myositis 58
Myositis 70

Characteristics:

Orphanet epidemiological data:

58
overlap myositis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare systemic and rhumatological diseases


External Ids:

Orphanet 58 ORPHA206572
UMLS 70 C0027121

Summaries for Overlap Myositis

MalaCards based summary : Overlap Myositis, also known as adult-onset overlap myositis, is related to juvenile overlap myositis and myositis, and has symptoms including muscle weakness, myoclonus and back pain. The drugs Infliximab and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include bone, skeletal muscle and eye.

Related Diseases for Overlap Myositis

Graphical network of the top 20 diseases related to Overlap Myositis:



Diseases related to Overlap Myositis

Symptoms & Phenotypes for Overlap Myositis

UMLS symptoms related to Overlap Myositis:


muscle weakness; myoclonus; back pain; myalgia; torticollis; sciatica; muscle cramp; muscle rigidity; muscle spasticity

Drugs & Therapeutics for Overlap Myositis

Drugs for Overlap Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 2, Phase 3 170277-31-3
2
Simvastatin Approved Phase 2, Phase 3 79902-63-9 54454
3
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
6
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
7
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
8
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
9
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
10
Azathioprine Approved Phase 3 446-86-6 2265
11
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
12
Abatacept Approved Phase 3 332348-12-6 10237
13
Sodium citrate Approved, Investigational Phase 3 68-04-2
14
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
15
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616
17
Zoledronic Acid Approved Phase 3 118072-93-8 68740
18
Denosumab Approved Phase 3 615258-40-7
19
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
20
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
21
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
22
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3 303-98-0 5281915
23
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26 Pharmaceutical Solutions Phase 2, Phase 3
27 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
28 Trace Elements Phase 2, Phase 3
29 Nutrients Phase 2, Phase 3
30 Vitamins Phase 2, Phase 3
31 Ubiquinone Phase 2, Phase 3
32 Micronutrients Phase 2, Phase 3
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3
34 Methylprednisolone Acetate Phase 3
35 Antimetabolites Phase 3
36 Citrate Phase 3
37 Antibiotics, Antitubercular Phase 3
38 Anti-Infective Agents Phase 3
39 Anti-Bacterial Agents Phase 3
40 Antifungal Agents Phase 3
41 glucocorticoids Phase 3
42 Immunoglobulins Phase 3
43 Antibodies Phase 3
44 Antibodies, Monoclonal Phase 3
45 Diphosphonates Phase 3
46 Antineoplastic Agents, Immunological Phase 2, Phase 3
47 Antirheumatic Agents Phase 2, Phase 3
48 Immunologic Factors Phase 2, Phase 3
49 Immunosuppressive Agents Phase 2, Phase 3
50 Alkylating Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
2 Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
3 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
4 Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI" Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
5 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
6 An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
7 Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02573467 Phase 3 Bimagrumab;Placebo
8 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
9 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
10 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial Recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
11 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Active, not recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
12 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Active, not recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
13 A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT03312634 Phase 3 Palovarotene
14 An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial Enrolling by invitation NCT04049097 Phase 3 Arimoclomol
15 A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS) Not yet recruiting NCT04789070 Phase 3 Sirolimus;Placebo
16 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
17 Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva Not yet recruiting NCT04577820 Phase 3 garetosmab
18 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Terminated NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
19 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
20 Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
21 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
22 Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM) Completed NCT02753530 Phase 2 Arimoclomol
23 A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
24 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
25 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
26 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
27 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Completed NCT02190747 Phase 2 Palovarotene;Placebo
28 Evaluation of Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis Recruiting NCT03912428 Phase 1, Phase 2 Celecoxib
29 A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome Recruiting NCT03215927 Phase 2 Abatacept
30 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
31 Saracatinib Trial TO Prevent FOP Recruiting NCT04307953 Phase 2 AZD0530 Difumarate;Matching placebo
32 A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan on Left Atrial Volume Index in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. Active, not recruiting NCT04687111 Phase 2 Sacubitril-Valsartan;Valsartan
33 A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT02279095 Phase 2 Palovarotene dose level 1;Palovarotene dose level 2;Palovarotene dose level 3;Palovarotene dose level 4
34 A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva Active, not recruiting NCT03188666 Phase 2 REGN2477;Matching placebo
35 A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT02979769 Phase 2 Palovarotene dose level 1;Palovarotene dose level 2
36 A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Low-dose Interleukin-2 in Combination With Standard Therapy Compared to Standard Therapy Alone in Adults With Active Idiopathic Inflammatory Myopathy Not yet recruiting NCT04237987 Phase 2 Interleukin-2;ciclosporin and corticosteroid
37 A Randomised, Phase IIa Treatment Delayed-start Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult Idiopathic Inflammatory Myopathy Not yet recruiting NCT04208464 Phase 2 Baricitinib;Baricitinib
38 Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy Not yet recruiting NCT04062019 Phase 2 Interleukin-2
39 A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Terminated NCT02521792 Phase 2 Palovarotene
40 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis Withdrawn NCT03710941 Phase 2 REGN2477+REGN1033;Matching placebo
41 Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis Unknown status NCT02483845 Phase 1 Natalizumab
42 Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis. Completed NCT01519349 Phase 1
43 An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis Completed NCT03440034 Phase 1 Pioglitazone
44 Kinesio Taping Effects Applied With Different Directions and Tensions on Electromyography, Electroencephalography, Local Temperature and Muscle Strength Completed NCT02501915 Phase 1
45 An Open-Label Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects Completed NCT04829773 Phase 1 Palovarotene;midazolam
46 Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Active, not recruiting NCT04421677 Phase 1 Phenylbutyrate Oral Tablet
47 A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Not yet recruiting NCT04659031 Phase 1 ABC008
48 Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects Not yet recruiting NCT04818398 Phase 1 DS-6016a;Placebo
49 High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial Terminated NCT00278564 Phase 1 Cyclophosphamide;Mesna;ATG(rabbit);Methylprednisolone;G-CSF;Rituxan
50 Risk of Muscle Damage in Cancer Patients Exposed to the Influenza Vaccine While Receiving Checkpoint Inhibitor Therapies: A Nested Case Control Study Using Claims Data Unknown status NCT03644498

Search NIH Clinical Center for Overlap Myositis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carisoprodol
Chlorphenesin
chlorphenesin carbamate
Chlorzoxazone
cyclobenzaprine
Cyclobenzaprine hydrochloride
metaxalone
Methocarbamol
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
tizanidine
tizanidine hydrochloride

Genetic Tests for Overlap Myositis

Anatomical Context for Overlap Myositis

MalaCards organs/tissues related to Overlap Myositis:

40
Bone, Skeletal Muscle, Eye

Publications for Overlap Myositis

Articles related to Overlap Myositis:

(show top 50) (show all 93)
# Title Authors PMID Year
1
The spectrum of idiopathic inflammatory myopathies in South Africa. 61
32212001 2021
2
Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort. 61
33423071 2021
3
Cutaneous Ulceration and Digital Gangrene in an Anti-MDA5-positive Overlap Myositis. 61
33752240 2021
4
Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. 61
33141387 2021
5
Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. 61
33360322 2021
6
A Case Report of Anorectal Squamous Cell Carcinoma Associated with Overlap Myositis Syndrome-a Possible Paraneoplastic Myositis Syndrome. 61
33736942 2021
7
External validation of the EULAR/ACR idiopathic inflammatory myopathies classification criteria with a Japanese paediatric cohort. 61
32810274 2021
8
Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. 61
33367878 2020
9
Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. 61
33458584 2020
10
From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies. 61
33314705 2020
11
The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease. 61
33211209 2020
12
Trends in idiopathic inflammatory myopathies: cross-sectional data from the German National Database. 61
32594219 2020
13
Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. 61
33099648 2020
14
Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. 61
32920327 2020
15
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. 61
32546599 2020
16
Inflammatory Myopathies: Utility of Antibody Testing. 61
32703475 2020
17
Outcomes of Pregnancy in Women With Inflammatory Myositis: A Cohort Study From India. 61
32732613 2020
18
Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. 61
31755959 2020
19
[Idiopathic Inflammatory Myopathies]. 61
32615605 2020
20
What is New in Idiopathic Inflammatory Myopathies: Mechanisms and Therapies. 61
33223661 2020
21
Secondary Causes of Myositis. 61
33041620 2020
22
Nailfold videocapillaroscopy alterations in dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy. 61
31440919 2019
23
Immune-Mediated Myopathies. 61
31794460 2019
24
Diagnostic value of additional histopathological fascia examination in idiopathic inflammatory myopathies. 61
31220379 2019
25
Acute sensorimotor polyneuropathy as an early sign of polyarteritis nodosa. A case report. 61
31788663 2019
26
Physical therapy in adult inflammatory myopathy patients: a systematic review. 61
31115788 2019
27
Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry. 61
30968571 2019
28
18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. 61
30664602 2019
29
Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. 61
30639643 2019
30
Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. 61
30392161 2019
31
Outcomes of Pregnancy in Women With Inflammatory Myositis: A Retrospective Cohort From India. 61
30720702 2019
32
Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. 61
30714969 2019
33
Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology. 61
30706861 2019
34
Muscle disease in scleroderma. 61
30148800 2018
35
The clinico-serological spectrum of overlap myositis. 61
30074509 2018
36
Classification and management of adult inflammatory myopathies. 61
30129477 2018
37
Immune checkpoint failures in inflammatory myopathies: An overview. 61
29885538 2018
38
C4d as a marker of complement activation in dermatomyositis muscle tissue. 61
30038095 2018
39
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. 61
29363513 2018
40
Revisiting Pathological Classification Criteria for Adult Idiopathic Inflammatory Myopathies: In-Depth Analysis of Muscle Biopsies and Correlation Between Pathological Diagnosis and Clinical Manifestations. 61
29522204 2018
41
Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy. 61
30116555 2018
42
Current Classification and Management of Inflammatory Myopathies. 61
29865091 2018
43
[Myositis: more than a muscle disease]. 61
29473539 2018
44
Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. 61
28866745 2017
45
Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: Descriptive Analysis. 61
27616211 2017
46
Profile of Pediatric Idiopathic Inflammatory Myopathies from a Tertiary Care Center of Eastern India. 61
28251541 2017
47
Sjögren's syndrome-associated myositis with germinal centre-like structures. 61
27988437 2017
48
[Diagnosis of Idiopathic Inflammatory Myopathy: A Muscle Pathology Perspective]. 61
27916753 2016
49
Myopathy in scleroderma and in other connective tissue diseases. 61
27548651 2016
50
Advances in serological diagnostics of inflammatory myopathies. 61
27538058 2016

Variations for Overlap Myositis

Expression for Overlap Myositis

Search GEO for disease gene expression data for Overlap Myositis.

Pathways for Overlap Myositis

GO Terms for Overlap Myositis

Sources for Overlap Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....